Page 204 - Read Online

Zhao et al. Hepatoma Res 2019;5:17 I http://dx.doi.org/10.20517/2394-5079.2018.116 Page 5 of 10

Figure 2. Tumor response comparing transarterial chemoembolization (TACE) plus stereotactic body radiation therapy (SBRT) with TACE
or SBRT monotherapy in intermediate-to advanced-stage hepatocellular carcinoma patients

Figure 3. Meta-analysis of the half-year survival in 4 studies comparing transarterial chemoembolization (TACE) plus stereotactic body
radiation therapy (SBRT) with TACE or SBRT monotherapy in intermediate-to advanced-stage hepatocellular carcinoma patients

Two-year survival rate
There were only 6 out of 13 studies included in the two-year survival follow up the group and the rest were not
added. No statistical heterogeneity was found among the studies, and a fixed-effect model was used (P = 0.930
> 0.1, I² = 0.00%). The results showed that the 2-year survival of the combined therapy group (TACE + SBRT)
was significantly higher than that of the monotherapy group (RR = 1.153, 95%CI: 1.282-1.783, P < 0.001). The
Egger test (P = 0.36738) and the Begg test (P = 0.57303) revealed no publication bias. The result of the two-year
survival rate was shown in [Figure 5].

The negative conversion rate of AFP
The negative conversion rate of AFP was reported in 6 studies. A random-effect model was used to analyse the
result on account of the statistical heterogeneity which was found among the studies (P = 0.045, I² = 56.00%).